Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986884 | 0.84 | FAAH (0.46) | FAAHMAPTCNR1CNR2TRPV1 | |
| SCHEMBL3556464 | 0.83 | — | — | |
| SCHEMBL9661123 | 0.81 | — | — | |
| SCHEMBL6420391 | 0.79 | MAPK1 (0.48) | FAAHTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL2987189 | 0.79 | TSHR (0.34) | FAAHTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL4812705 | 0.77 | TSHR (0.33) | FAAHTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL33485 | 0.77 | FAAH (0.40) | FAAHTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL14991062 | 0.77 | CA1 (0.39) | FAAHTSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL502266 | 0.73 | FAAH (0.50) | FAAHMAPK1LMNACNR1CNR2 | |
| SCHEMBL16241152 | 0.73 | ALDH1A1 (0.32) | FAAHTSHRCHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104974188-A | Tenofovir disoproxil crystal form and preparation method thereof | ZHEJIANG JIUZHOU PHARM CO LTD | 2015-10-14 | — | — | CN | claimed |
| CN-104974188-B | A kind of tenofovir disoproxil crystal form and preparation method thereof | 浙江九洲药业股份有限公司 | 2019-01-08 | — | — | CN | disclosed |
| CN-104974188-A | Tenofovir disoproxil crystal form and preparation method thereof | ZHEJIANG JIUZHOU PHARM CO LTD | 2015-10-14 | — | — | CN | disclosed |
| CN-101463045-B | Thiophosphate nucleotide compound | HEFEI HENGXING PHARMACEUTICAL INST | 2011-08-31 | — | — | CN | disclosed |
| CN-101921294-A | Substituted benzodihydropyran derivatives and anti-tumor application thereof | ANHUI HUAKANG MEDICINE TECHNOLOGY DEV CO LTD | 2010-12-22 | — | — | CN | disclosed |
| US-7737273-B2 | Process for acyclic phosphonate nucleotide analogs | HETERO DRUGS LIMITED (IN) | 2010-06-15 | — | — | US | disclosed |
| US-7737273-B2 | Process for acyclic phosphonate nucleotide analogs | HETERO DRUGS LIMITED (IN) | 2010-06-15 | — | — | US | disclosed |
| CN-101463045-A | Thiophosphate nucleotide compound | HEFEI HENGXING PHARMACEUTICAL (CN) | 2009-06-24 | — | — | CN | disclosed |
| US-20090012292-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | HETERO DRUGS LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| US-20090012292-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | HETERO DRUGS LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1243593-A2 | Nucleotide analog composition and synthesis method | GILEAD SCIENCES, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6069249-A | CHEMICAL INTERMEDIATES; DETECTION LABELS FOR NUCLEOTIDE PROBES | GILEAD SCIENCES, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0998480-A1 | NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD | GILEAD SCIENCES, INC. (US) | 2000-05-10 | — | — | EP | disclosed |
| US-6043230-A | Use of tenofovir disoproxil fumarate in treatment of HIV | GILEAD SCIENCES, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5935946-A | TENOFOVIR DISOPROXIL FUMARATE; ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5922695-A | COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS | GILEAD SCIENCES, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1999005150-A1 | NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012292-A1 | NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS | TYMP, DUT, DPYD | FAAH 1215/4885TSHR 3877/4885CHRM2 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.